TrialThe New England journal of medicine2012
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire Harrison et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
922 papers cite itlatest 60 shown
this paperpooled ittrialcites it